Improvement of masseter spasticity by botulinum toxin facilitates PEG placement in amyotrophic lateral sclerosis.
Restivo
Domenico A
DA
Lanza
Sara
S
Marchese-Ragona
Rosario
R
Palmeri
Agostino
A
D000690:Amyotrophic Lateral Sclerosis / Q000150:complications*; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D003680:Deglutition Disorders / Q000209:etiology*; D005774:Gastrostomy; D006801:Humans; D008406:Masseter Muscle / Q000187:drug effects*; D009128:Muscle Spasticity / Q000188:drug therapy* / Q000209:etiology; D009465:Neuromuscular Agents / Q000627:therapeutic use*
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A